Cancer is becoming one of the main causes of mortality across the globe. According to the World Health Organization (WHO), cancer was the top cause of death for individuals under the age of 70 in 183 nations, while in 123 other countries, it was the fourth most common cause of death globally in 2019. Furthermore, according to the data released by the World Health Organization in March 2021, ~10 million fatalities were attributed to various forms of cancer in 2020. The market under consideration has shown significant expansion, which can be linked to the rising frequency of cervical cancer among women worldwide. According to the World Health Organization (WHO), cervical cancer kills more than 270,000 women each year. Cervical cancer mortality rates are greater in poorer nations due to the late discovery of the disease.
The increasing prevalence of cervical cancer has created a burden on the healthcare systems across the world. According to the International Agency for Research on Cancer (IARC), the global burden of new cancer cases is estimated to reach ~27.5 million, and the disease is likely to cause ~163 million deaths by 2040. Factors such as lifestyle changes, smoking, reduced physical activities, and uncertain health and climatic conditions are likely to increase the burden of cancer in the world. Across the globe, cancer is becoming one of the main causes of mortality. Therefore, controlling and preventing the increasing number of cancers worldwide is essential.
The cervical cancer treatment market analysis has been carried out by considering the following segments: type, product, and end user. By type, the market is classified into squamous cell carcinoma,
adenosquamous carcinoma, and adenocarcinoma. Based on product, the market is divided into surgery
radiation therapy, chemotherapy, immunotherapy, and therapeutic vaccines. By end user, the market is segmented into hospital, homecare, cancer centers, and others. The geographic scope of the cervical cancer treatment market report includes North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). In 2022, North America held the largest cervical cancer treatment market share. In North America, the US holds a significant market share. Constantly ongoing R&D activities, financial assistance from governments and other public and private organizations, partnerships between IT and pharmaceutical firms, and the rising incidences of neurological diseases primarily drive market growth in the country. Furthermore, strategic initiatives taken by the government to improve the testing procedures are anticipated to benefit the market during the forecast period. The increasing adoption of regulations pertaining to rare diseases will most likely present an opportunity for market expansion. For example, the American Cancer Society (ACS) revised the cervical cancer screening standards in September 2020.
The cervical cancer treatment market analysis is carried out by identifying and evaluating key players in the market across different regions.
Cervical Cancer Treatment Market: Competitive Landscape and Key Developments
F. Hoffmann-La Roche Ltd, Merck Sharp, Dohme Corp., GlaxoSmithKline plc., Genentech Inc., Amgen Inc., Advaxis Inc., Biocon, Allergan Inc., Pfizer Inc., and AstraZeneca are a few key companies operating in the cervical cancer treatment market . Key market players adopt product innovation strategies to meet evolving customer demands and maintain their brand image.